March 2020 New England Journal of Medicine article studying the effects of Rivaroxaban in Peripheral Artery Disease after Revascularization. Results revealed rivaroxaban (2.5mg twice daily) plus aspirin was associated with a significantly lower incidence of adverse outcomes such as heart attack and stroke when compared with aspirin alone. In this international study involving 34 countries, Dr. Szalay was the Canadian site lead.

Read more here.